Rigel is a South San Francisco biotechnology company that develops and sells medicines for blood disorders and cancer. It last closed at $42.92 on Nov 17, down 1.85% on the day. The average 12-month price target from 3 analysts is $63.33 (+47.6% from the last close), with a high of $86.00 and a low of $47.00. Analyst consensus is Buy, based on the latest ratings from 3 firms (2 buy, 1 hold, 0 sell).
Each firm's latest rating on RIGL in the past 90 days
Average 12-month target
$63.33
▲ 47.6% upside
Based on 3 analysts who set a price target on RIGL in the past 90 days. The average target is $63.33, with a high of $86.00 and a low of $47.00, compared with the last close of $42.92.
Low $47.00Avg $63.33High $86.00
Blue marker: last close $42.92
Highest target$86.00
Average target$63.33
Lowest target$47.00
Latest rating changes
CitigroupMaintained
Nov 9Buy$86
Cantor FitzgeraldMaintained
Nov 6Hold$47
HC Wainwright & Co.Target lowered
Sep 25Buy$85 → $57
Piper SandlerMaintained
Aug 17Hold$49
HC Wainwright & Co.Target raised
Aug 14Buy$57 → $85
Date
Firm
Action
Rating
Price target
Nov 9
Citigroup
Maintained
Buy
$86
Nov 6
Cantor Fitzgerald
Maintained
Hold
$47
Sep 25
HC Wainwright & Co.
Target lowered
Buy
$85 → $57
Aug 17
Piper Sandler
Maintained
Hold
$49
Aug 14
HC Wainwright & Co.
Target raised
Buy
$57 → $85
Loading…
Technical Analysis
RIGL · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend
The stock is 10% below its 20 day and 10% below its 50 day average. It is 12% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 41). The nearest support is the Pivot at $42.83, and the nearest resistance the swing high (Jul 16) at $43.34.
Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 5.6%/day
Key levels
$52.6152 week high+22.6%
$47.2550 day average+10.1%
$47.1620 day average+9.9%
$44.64100 day average+4.0%
$43.57Pivot R1+1.5%
$43.34Swing high (Jul 16)+1.0%
$42.92Last close
$42.83Pivot−0.2%
$42.19Pivot S1−1.7%
$37.66200 day average−12.3%
$37.60Swing low (Nov 6)−12.4%
$24.9552 week low−41.9%
Indicators
RSI (14)
40.89
Middle of its range
Neutral
MACD
-1.20
Below its signal line
Bearish
Stochastic
40.7
Middle of its range
Neutral
ADX (14)
22.4
Weak trend
Williams %R
-64.6
Oversold below −80, overbought above −20
Neutral
CCI (20)
-89.8
Oversold below −100, overbought above 100
Neutral
Rate of change
−12.2%
Change over 10 sessions
Bearish
ATR (14)
$2.41
Typical daily range, 5.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
Rising
Short trendBullish
Long trendNot enough history
MomentumFading
StretchNormal
VolatilityNormal, 11.3%/day
Key levels
$52.6152 week high+22.6%
$47.2550 day average+10.1%
$47.1620 day average+9.9%
$44.64100 day average+4.0%
$43.57Pivot R1+1.5%
$43.34Swing high (Jul 16)+1.0%
$42.92Last close
$42.83Pivot−0.2%
$42.19Pivot S1−1.7%
$37.66200 day average−12.3%
$37.60Swing low (Nov 6)−12.4%
$24.9552 week low−41.9%
Indicators
RSI (14)
50.87
Middle of its range
Neutral
MACD
2.44
Below its signal line
Bearish
Stochastic
33.7
Middle of its range
Neutral
ADX (14)
27.1
Trending down
Williams %R
-64.6
Oversold below −80, overbought above −20
Neutral
CCI (20)
-21.7
Oversold below −100, overbought above 100
Neutral
Rate of change
−9.1%
Change over 10 sessions
Bearish
ATR (14)
$4.84
Typical daily range, 11.3% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200–
What happened before, for RIGL
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how RIGL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow RIGL usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How RIGL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RIGL is in one of them and how their past RIGL trades turned out.
Rigel is a biotechnology company based in South San Francisco, California, that develops and sells medicines for patients with blood disorders and cancer. Its approved products include TAVALISSE, an oral medicine for adults with chronic immune thrombocytopenia, REZLIDHIA for certain adults with relapsed or refractory acute myeloid leukemia, and GAVRETO for certain lung and thyroid cancers. The company is also developing other treatments, including an experimental drug for a blood disorder called myelodysplastic syndrome.